As reported by others,6 traditional screening criteria do not perform well for identifying PV in PDAC and would have missed 56% patients with PVs in our study including those in BRCA2, ATM, and MSH2, which have implications for cancer risk‐reduction strategies and screening and surveillance in healthy family members and for which management guidelines have been developed. This evidence concerns the gene BRCA2 and acquired polycythemia vera.